Latest news with #PanTracer


Business Wire
a day ago
- Business
- Business Wire
NeoGenomics Launches PanTracer LBx, Expanding Access to Comprehensive Genomic Profiling with Liquid Biopsy
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling (CGP) test, expanding the company's PanTracer portfolio. PanTracer LBx is a noninvasive test designed to support therapy selection, trial matching, and longitudinal monitoring, empowering data-driven decisions even when tumor tissue is limited or unavailable. 'The launch of our liquid biopsy test positions us at the forefront of the precision oncology market,' said Tony Zook, Chief Executive Officer, NeoGenomics. 'As demand grows for faster, less invasive, and more accessible genomic testing, PanTracer LBx expands our addressable market, enhances our clinical portfolio, and opens new revenue streams in both therapy selection, trial matching, and disease monitoring. It's a strategic milestone that underscores our commitment to sustainable growth and clinical leadership.' Using circulating tumor DNA (ctDNA) from a simple blood draw, PanTracer LBx provides access to biomarker information when tissue samples are insufficient or unavailable. The test is designed to offer a seven-day turnaround time and analyze over 500 genes, including MSI and bTMB, to deliver timely, actionable insights. When indicated, it can be ordered as a standalone option, as a reflex when tissue testing fails, or concurrently with tissue analysis. Clinical applications include therapy selection, trial matching, and longitudinal monitoring. PanTracer LBx strengthens NeoGenomics' pan-solid tumor CGP portfolio, working seamlessly with tissue-based options like PanTracer Tissue, providing a testing strategy across a range of solid cancers. Complemented by a broad portfolio of testing services and dedicated clinical support, the launch expands NeoGenomics' position in the growing $3–5 billion liquid biopsy market and advances its goal of delivering deep insights to more patients across diverse care settings. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'can,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the potential impact of PanTracer™ LBx in oncology treatment and clinical trial enrollment. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the extent of use by oncologists and biopharma companies of PanTracer™ LBx, the speed and utility of the results generated, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and in the 'Investors' section of our website at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.


Associated Press
30-06-2025
- Business
- Associated Press
NeoGenomics Announces PanTracer Tissue and PanTracer Tissue + HRD Now Available to Support More Informed and Timely Cancer Care
FORT MYERS, Fla.--(BUSINESS WIRE)--Jun 30, 2025-- NeoGenomics, Inc. (NASDAQ: NEO) , a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the launch of PanTracer™ Tissue, a next-generation solid tumor profiling assay, including the option to add testing for homologous recombination deficiency (HRD). These new options can provide faster, actionable insights to help physicians navigate complex treatment decisions more confidently. PanTracer Tissue evaluates over 500 cancer-related genes and aligns with clinical guidelines, covering key biomarkers recommended for therapy selection and additional genomic insights for clinical trial enrollment. Results may be delivered in as little as 8 days, enabling physicians to rapidly initiate treatment strategies. Minimal specimen requirements make it suitable for a wide range of tumor types and practice settings. The assay builds on the company's tissue-based CGP platform, previously known as NeoComprehensive ® Solid Tumor. The addition of PanTracer Tissue + HRD offers enhanced tumor profiling by incorporating homologous recombination deficiency analysis into a single, guideline-aligned test for ovarian cancer. The PanTracer Tissue + HRD offering includes BRCA mutation status and a genomic instability score—critical biomarkers that can help guide the use of PARP inhibitors and other therapies targeting DNA repair pathways. The combined approach streamlines ordering and can shorten time to actionable results by capturing a broader range of clinically relevant genomic alterations, gene fusions, and DNA repair deficiencies. 'With PanTracer Tissue and PanTracer Tissue + HRD we're unlocking a more complete genomic view from a single sample, giving physicians clearer answers, sooner,' said Warren Stone, President and Chief Operating Officer at NeoGenomics. 'With the addition of PanTracer Tissue + HRD, we are expanding our portfolio to address the unmet need for ovarian cancer therapy selection with the objective of improving patient care.' PanTracer Tissue and PanTracer Tissue + HRD are part of NeoGenomics' broader portfolio of precision oncology solutions designed to improve patient outcomes through high-quality, guideline-aligned testing. Revealed at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, the continually expanding PanTracer portfolio reflects the company's dedicated focus on advancing diagnostic tools that support more informed, personalized care. About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'can,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including statements regarding the potential impact of PanTracer™ Tissue, including the use of HRD testing, in oncology treatment and clinical trial enrollment. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the extent of use by oncologists and biopharma companies of PanTracer™ Tissue + HRD, the speed and utility of the results generated, and the risks identified under the heading 'Risk Factors' contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at and in the 'Investors' section of our website at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. View source version on CONTACT: Investor Contact Kendra Webster [email protected] Contact Andrea Sampson [email protected] KEYWORD: UNITED STATES NORTH AMERICA FLORIDA INDUSTRY KEYWORD: RESEARCH MEDICAL DEVICES GENETICS CLINICAL TRIALS BIOTECHNOLOGY RADIOLOGY HEALTH SCIENCE ONCOLOGY SOURCE: NeoGenomics, Inc. Copyright Business Wire 2025. PUB: 06/30/2025 07:05 AM/DISC: 06/30/2025 07:05 AM
Yahoo
23-05-2025
- Business
- Yahoo
NeoGenomics introduces c-MET companion diagnostic for NSCLC
NeoGenomics has commercially launched the c-MET Companion Diagnostic (CDx) for use in non-small cell lung cancer (NSCLC), offering a 48-hour turnaround for oncologists and pathologists. This new immunohistochemistry (IHC) assay is designed to detect the overexpression of c-Met (mesenchymal-epithelial transition factor) protein, which is found in up to half of individuals with advanced NSCLC. The c-MET CDx for NSCLC assay is intended to detect individuals who may benefit from targeted therapies such as AbbVie's Emrelis (telisotuzumab vedotin-tllv), which was recently approved by the US Food and Drug Administration (FDA). Developed in line with the regulator's guidance, the assay is said to be validated for use with MET-targeted treatments while enabling timely clinical decision-making. NeoGenomics noted that the assay complements the company's PanTracer portfolio, which includes genomic and immuno-oncology markers. It forms part of the company's extensive NSCLC testing offerings, supporting the adoption of MET-directed treatments and the advancement of precision cancer care. Headquartered in the US, NeoGenomics focuses on cancer genetics testing and information services and provides a range of oncology-focused tests. NeoGenomics medical services vice-president Dr Nathan Montgomery said: 'Accurate and timely biomarker testing is critical in lung cancer, where targeted therapies can meaningfully change the course of a patient's treatment. 'The c-MET CDx for NSCLC assay adds an important tool to our testing portfolio, helping oncologists quickly identify patients who may benefit from MET-directed therapies. It also complements our PanTracer suite, enabling comprehensive biomarker profiling for NSCLC.' In October 2024, the company announced the receipt of conditional approval from the New York State Department of Health for two next-generation sequencing (NGS) tests, the Neo Comprehensive Solid Tumor assay and the NeoTYPE DNA & RNA Lung. "NeoGenomics introduces c-MET companion diagnostic for NSCLC" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data